Summary Eighteen patients with advanced cancer have been treated intravenously with human recombinant tumour necrosis factor (rhTNF). The drug produced febrile reactions at all doses although these were preventable by steroids and indomethacin. Doses at or above 9 x 105 units (400 pg)m-2 were associated with hypotension, abnormal liver enzymes, leucopenia and mild renal impairment in a substantial proportion of patients. RhTNF was cleared from plasma with a half life of -20 minutes but non-linear pharmacokinetics were seen with decreased clearance at higher doses. In 3 patients, all with lymphoma, improvements in their tumours were recorded.
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RhTNF was noted to produce rapid increases in serum C-reactive protein concentrations. Endogenous TNF levels were not found to be elevated in 72 cancer patients.
TNF deserves further therapeutic evaluation and these observations support its biological importance as an endogenous pyrogen, mediator of acute phase protein responses, and a mediator of endotoxic shock.
Tumour Necrosis Factor (TNF) is a protein released by activated macrophages in response to stimulation by endotoxin. It was originally described in the serum of mice treated with Bacillus Calmette-Guerin and bacterial endotoxin and its characteristic effect in vivo is the production of necrosis in experimental animal tumours (Carswell et al., 1975; Matthews & Watkins, 1978; Matthews, 1978) . It has diverse biological effects in other experimental systems including killing of tumour cells in vitro (Old, 1985) , inhibition of the activity of lipoprotein lipase (cachectin activity) (Beutler & Cerami, 1987) ; mediation of some of the lethal effects of endotoxin in animals (Beutler et al., 1985) , stimulation of granulocytes and fibroblasts (Old, 1985; Beutler & Cerami, 1987; Vilcek et al., 1986) , damage to endothelial cells (Sato et al., 1986) , bone resorption (Bertolini et al., 1986) , antiviral activity (Mestan et al., 1986; Wong & Goeddel, 1986) and cytotoxic effects against malarial parasites (Taverne et al., 1981 (Taverne et al., ,1984 . Raised serum TNF levels are associated with some infections in man (Scuderi et al., 1986; Waage et al., 1987) . Macrophageproduced TNF (which we have studied) is sometimes referred to as TNF alph-a to distinguish it from lymphocytotoxin, a closely related lymphocyte-product which may be called TNF beta (Pennica et al., 1984) .
The gene for human TNF has now been cloned and expressed in E. coli making large quantities of human recombinant TNF (rhTNF) available for experimental and clinical evaluation (Pennica et al., 1984; Shirai et al., 1985; Wong et al., 1985; Marmenout et al., 1985) . It is a nonglycosylated protein containing 155 amino acids of relative molecular weight 17,000 usually arranged in multimeric form. Initially a propeptide with an additional 76 amino acids is synthesised and both precursor and mature protein are about 80% conserved between mouse and man (Old, 1985; Beutler & Cerami, 1987; Pennica et al., 1984; Shirai et al., 1985; Wong et al., 1985; Marmenout et al., 1985) . The gene in man is located on chromosome 6 (Nedwin et al., 1985) . TNF interacts with high affinity receptors (Rubin et al., 1985; Kull et al., 1985) although its anti-cancer effect could be mediated indirectly, in-vivo, perhaps via endothelial cell damage.
The precise physiological role of TNF and its role in disease is unclear. A pathophysiological role in cancer cachexia is possible in man (Beutler & Cerami, 1987) probably mediates some aspects of endotoxic shock (Beutler et al., 1985; Waage et al., 1987) . TNF is a candidate for the biological treatment of cancer in view of its well established activity against experimental cancer. We administered rhTNF to cancer patients in order to find the maximum tolerated dose, study its pharmacokinetics and make an initial evaluation of its anticancer effect. We were also able to make some observations which may contribute to our understanding of the biology of TNF in man.
Patients, materials and methods

Study design
New biological materials present special difficulties for early pharmacological studies. Toxicity is unpredictable and major species differences between tested species and man are possible. We adopted a low starting dose and cautious dose escalation.
Human recombinant TNF is lethal to 10% of mice at a dose of 9 x 106 units m-2 i.v. The conventional starting dose for studies with a new anti-cancer drug with this toxicity in mice would therefore have been 9 x 105 units m-2 (Von Hoff et al., 1984) . We elected to begin treatment at a dose of 9 x 103units m-2 (3 patients). The study design allowed a patient to receive 2 treatments at the initial dose separated by 2 weeks and then one dose escalation for the third dose, 2 weeks later (Table I) . Dose levels for escalation were: 9 x 104 unitsm-2 (6pts), 3 x 105 unitsm-2 (6pts), 6 x 105 unitsm-2 (5pts), 9 x 105 unitsm-2 (7pts), 1.2 x 106unitsm-2 (2pts).
Between 3 and 5 patients began treatment at each dose 
TNF
Human recombinant TNF was provided by the Asahi Chemical Industry Company prepared as previously described (Shirai et al., 1985) . It is highly purified and there is no evidence of residual bacterial endotoxin. Freeze-dried TNF was stored at +4°C and reconstituted in sterile water and then further diluted in 100mls saline, before administration over 1 h i.v. The specific activity of the preparation was 2.2 x 106 units mg-1. A unit is arbitrarily defined as the reciprocal of the dilution required to produce 50% cell survival in-vitro for a sensitive murine cell line (L-M cells A range of manoeuvres were tried to minimise the acute reactions using corticosteroids, sedatives, non-steroidal antiinflammatory drugs and antihistamines. No treatment seemed to modify established reactions. Hydrocortisone and chlorpheniramine pre-treatment were ineffective. Pretreatment with i.v. methyl prednisolone (250-500 mg) 2 h before TNF and oral indomethacin (50 mg) dramatically reduced the rigors, fevers, tachycardia and hypertension. Sixteen of 23 patients who received this prophylaxis experienced no reaction to TNF at all and in the others they were only mild. The controllable acute febrile reactions were not considered a dose-limiting toxicity. However, as higher doses of rhTNF were given several other toxicities were seen:
Hypotension Mild hypotension was seen at doses of TNF less than 9 x l05u m-2 with minimum b.p. 105/60 (median) and no systolic pressure <80 mm Hg and/or diastolic <55mm Hg. However, at a dose of 9x105um-2, 3/7 patients developed hypotension with diastolic <50mm Hg and/or systolic <80 mm Hg and in one case this was severe 50/35 (from baseline 120/60) and life threatening requiring i.v. fluids and a dopamine infusion. A fall in blood pressure (40mm and 20mm of Hg systolic respectively) occurred in both patients treated at 1.2x 106um-2. Hypotension was most severe 6-12 h after TNF and occurred despite the use of methyl prednisolone pre-treatment. One patient developed minimum b.p. of 90/40 after 9 x 105 um-2 but only 115/55 after 6 x 105 um-2 which also supports the dose relationship of the hypotension.
Abnormal hepatic enzymes No substantial abnormalities in LFTs were seen at or below a dose of 3 x 105 um-2. Two of 5 patients who received 6 x 105um-2 and 3 of 7 patients who received 9 x 105 um-2 developed transient abnormalities of more than WHO grade II (WHO, 1979) severity in one or more hepatic enzyme usually alkaline phosphatase. All returned to pre-treatment levels before the next dose of TNF. No cummulative abnormalities were noted with repeated treatments.
Changes in white cell count No changes were seen at doses of 9 x 103 um-2. Between 9 x 104 and 6 x l05 unitsm-2 most patients developed neutrophil leucocytosis of 16-30 x 109 1-1 at 24 h returning to normal over a further 24 h. At a dose of 9xl05um-2 profound leucopenia developed in 4 of 7 patients and was less than 1 x 109 leucocytes 1-1 in 3 patients. This was very short-lived and white cell counts returned to normal levels at 24 h. Acute phase proteins Serum C-reactive protein concentration was measured before and 24h after rhTNF (6-9 x lO m-2) in 7 patients. In 3 of these levels were taken for 2 treatments and in one patient for 3 treatments. Results are shown in Figure 1 Figures 2(a, b ) and 3 and in Table II . No rhTNF was detected in the urine.
In 8 patients, the concentrations of rhTNF fell exponentially on at least one occasion (as shown for 2 patients in Figure 2 ) and median half life was 17 min (range 8-61 min). In the remaining 9 patients, the plasma decay curves were not exponential and half lives were not calculated. In 3 of these 9 patients the data were scattered and no satisfactory shape to the plasma concentration curves could be discerned. In 6 patients the curves (log concentration vs. time) were convex upwards (as illustrated for one patient in Figure 2b ) with less steep slopes at higher concentrations. In two patients who showed exponential fall in plasma concentrations on one occasion, convex-upwards curves were seen on other occasions (Figure 2) .
Peak plasma concentrations were read directly from the curves and areas under the plasma concentration-times curves were estimated by the trapezoid rule and clearance calculated from this (Table II) . Peak concentration and AUC increased with dosage. However, clearance of TNF fell with increasing dose (Figure 3 ) demonstrating non-linear pharmacokinetics. There was considerable variation between patients and somewhat less between studies in the same patient. These may be compared at a dosage of 6 x 10 um-2 where most replication of measurements was possible and the coefficient of variation (standard deviation/mean %) of AUC between patients was 45% whereas the average coefficient of variation of results within one patient was 27%. (Playfair et al., 1982) . However, it must be emphasised strongly that it is difficult to draw conclusions about a consistent anticancer effect in man from these studies and we do not claim on the basis of the available evidence that this drug has yet been shown to be significant new treatment. The occurrence of fevers and rigors after low doses of TNF suggests that it is an endogenous pyrogen. In rabbits TNF is pyrogenic directly as well as by the release of interleukin 1 which results in a biphasic fever (Dinarello et al., 1986) . There is no evidence of biphasic fever in man. Apart from the production of fever, the toxicity pattern suggests that TNF may mediate hypotension, abnormal liver function tests and renal failure in some infectious diseases. This suggestion is supported by the observation in experimental animals that anti TNF antibodies reduce fatalities resulting from experimental infections (Beutler et al., 1985) and the association of high TNF levels with fatal meningococcal infection (Waage et al., 1987) . It is possible that the production of TNF may also have a role in the defence against infections. The activity of the material against parasites in vitro and the observation that serum TNF levels are elevated in some parasitic infections (Scuderi et al., 1986) would support this suggestion.
We have found no evidence of elevation of serum TNF levels in any patients with malignant disease and this agrees with some other results (Scuderi et al., 1986) . However, we are using a double-antibody method to measure intact TNF and have only looked at cryopreserved samples. It is possible that the production of TNF from peripheral blood monocytes is increased in cancer patients (Aderka et al., 1985) and we are exploring this possibility.
A role for TNF in mediation of the acute phase protein response in animals has already been proposed (Dinarello, 1986) . Moreover, there is evidence that TNF may regulate the expression of hepatic acute phase protein genes in vitro (Perlmutter et al., 1986) . The data presented here suggests that TNF may indeed mediate the production of some acute phase proteins in man.
TNF appears to be of considerable biological importance although its role as a cancer therapy will only become clear when further studies have evaluated treatment at doses which we have found to be tolerated and more frequent administration. The combination of TNF with other biological agents such as gamma interferon has been shown in experimental systems to be strongly synergistic (Aggarwal et al., 1985; Fransen et al., 1986; Balkwill et al., 1987 ) and this will justify clinical evaluation of the combination. Combinations of biological agents with conventional cytotoxic drugs appear also to be effective in experimental systems and deserve consideration (unpublished data).
